IMPACT Non Hodgkins Lymphoma (NHL) Study

NCT00903812 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1837

Last updated 2018-07-06

No results posted yet for this study

Summary

This is multi-center, international observational study of subjects receiving CHOP-14 or CHOP-21 (with or without Rituximab) for the treatment of NHL. Approximately 100-150 sites will contribute information on subjects treated at their institution.

Conditions

  • Non-Hodgkin's Lymphoma

Interventions

OTHER

No intervention

No intervention as observational study

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2008-12-31
Completion
2014-03-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00903812 on ClinicalTrials.gov